Skip to Main Content
Pharmacist's Letter Canada
Menu
    • Products
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • Natural Medicines
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber's Letter
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Charts
    • Natural Medicines Resources
  • CE & Training
    • CE Organizer
    • Available Courses
    • Live CE Calendar
    • Print Statements
    • Licenses
    • Additional Requirements
    • Exemptions
  • New Drugs
  • Help
    • User Support
    • Contact Us

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

New! RxAdvanced: Guide to Cannabis training for pharmacists that offers 16 hours of ACPE-accredited training based on the latest, science-based cannabis research. Only $199. Learn More!
  1. Home
  2. Browse
  3. Renal & Urology
  4. UTIs

UTIs

  • Benign Prostatic Hypertrophy (11)
  • Cystitis (3)
  • Drug-Induced Nephrotoxicity (86)
  • Drug Use in Renal Insufficiency (197)
  • Hyperkalemia (11)
  • Hypokalemia (1)
  • Hyponatremia (2)
  • Incontinence (2)
  • Kidney Disease (33)
  • Kidney Stones (11)
  • Nephrology (40)
  • Overactive Bladder (21)
  • Resources (57)
  • Urinary Retention (6)
  • UTIs (65)
  • Urine Drug Testing (10)
31 - 45 of 65 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
PL Voices: Limiting the Use of Quinolones January 2016
PL Voices: Appropriate Medication Use in Older Adults: 2015 Updated Beers Criteria December 2015
Article: Think of Beers Criteria as a "Warning Light" Rather Than a "Stop Sign" December 2015
PL Voices: Cardiovascular Outcomes with Empagliflozin (Jardiance) November 2015
Commentary: Empagliflozin and Cardiovascular Disease November 2015
Article: Don't be too Quick to Jump on the Jardiance (empagliflozin) Bandwagon November 2015
Article: Don't Recommend Routine Prophylaxis for Kids With Recurrent UTIs April 2015
Article: Don't Start Antibiotics Based Just on Pyuria April 2015
Commentary: Asymptomatic Bacteriuria FAQs April 2015
Commentary: Prophylactic Antibiotics for Children with Recurrent UTIs April 2015
Article: Think of Forxiga as Similar to Invokana for Type 2 Diabetes March 2015
Commentary: Antimicrobial Stewardship November 2014
PL Voices: Safety of Quinolone Antibiotics in Children August 2014
Article: safety of systemic quinolones in KIDS August 2014
Article: Invokana (in-vo-KAHN-uh, canagliflozin), as the first in a new class of oral drugs for type 2 diabetes July 2014
  • « Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
  • About Us
  • Our Mission
  • Our Team
  • Testimonials
  • Careers
  • Newsroom
  • Products
  • Pharmacist Solutions
  • Prescriber Solutions
  • Hospital Solutions
  • Retail Solutions
  • Group Practice Solutions
  • Support & Policies
  • Contact Us
  • Access Agreement
  • Privacy Policy

The contents of this website are not intended to be a substitute for professional medical advice, diagnosis, or treatment. See additional information.

© Therapeutic Research Center. All Rights Reserved